Searched for
REVLIMID MARGIN PRESSURES
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Strait of Hormuz is now India's biggest market risk, says Ashi AnandIndian markets await clarity on Strait of Hormuz shipping. Ashi Anand of IME Capital suggests a defensive market approach. Oil prices near ...
- Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business press...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Pharma and healthcare companies to face continued margin pressure: HDFC SecuritiesThe Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the Marc...
- Q3 results today: Eternal among 59 companies to report earnings on WednesdayIndian markets brace for a busy earnings day with 59 companies reporting Q3 results. Investors are keenly watching Eternal's expected stron...
- Dr Reddy's Q3 preview: PAT may fall 22% YoY as US pressure to weigh on earningsDr Reddy's Laboratories anticipates a subdued performance for the December quarter. Pressure from its United States business is expected to...
- Sun Pharma Q2 Preview: PAT may rise 2% YoY; Leqselvi spending to weigh on marginsSun Pharma is expected to report modest Q2 FY26 earnings growth, with PAT likely up 2% YoY and revenue rising 7%. Analysts cite Leqselvi la...
- Dr Reddy’s Q2 Preview: PAT may grow up to 11–18% YoY; revenue seen steady despite pricing pressure in USDr Reddy’s Laboratories is expected to post steady September-quarter earnings with 10–14% revenue growth led by India and Europe, though US...
- Can US generics momentum and CDMO strength keep pharma earnings steady this quarter?Indian pharmaceutical companies are set for a steady September quarter. Growth in the US generics market and domestic sales will drive perf...
- Dr Reddy’s Q1 Results Preview: PAT may grow up to 15% YoY, revenue to surge up to 19%Dr Reddy’s Q1FY26 earnings are expected to show steady revenue growth and resilient domestic demand, with mixed profit estimates ranging fr...
- Drug companies set for improved revenue growth in June quarter amid US market challengesIndian pharma and healthcare companies anticipate improved revenue and profit in the June 2025 quarter, fueled by domestic market growth. H...
- Cipla faces revenue and margin pressure ahead of Revlimid patent expiryCipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Mar...
- Dr Reddy’s Labs Q4 Preview: PAT may jump up to 12% YoY, revenue to rise up to 18% on generics business doseDr Reddy’s Q4FY25 net profit is expected to grow 1.3–12% YoY, with revenues likely rising 13–18% to ₹7,981–8,424 crore, according to broker...
- Dr. Reddy’s Laboratories shares in focus on denial of workforce reductionDr. Reddy’s Laboratories shares: In a regulatory filing, the pharmaceutical giant addressed a Business Standard article dated April 13, whi...
- Capacity push and new drugs critical for Aurobindo's healthA delay in drug approvals in the US market remains a concern for Aurobindo. The company stated that eight ANDAs (abbreviated new drug appli...
- Pharma Q2 Preview: Cipla to see steady quarter; higher profit and revenue growth for Dr Reddy'sCipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on...
- Dr Reddy’s Labs net profit doubles in Q1: What should investors do?Share of the pharma major fell about 4 per cent in the first one hour of the trade on Friday. Experts see concerns over the US business, as...
Load More
